Argos Therapeutics Inc. (NASDAQ:ARGS)

Argos Therapeutics Inc. (NASDAQ:ARGS) Balance Sheet Receives $1.5 Million

Argos Therapeutics Inc. (NASDAQ:ARGS)

Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) fell 8.76% after the immuno-oncology company announced a receipt of $1.5 million milestone payment from Lummy Co Ltd. The payment pertains to a technology transfer for the manufacturing of Rocapuldencel-T.

Argos Therapeutics Inc. (NASDAQ:ARGS)

Argos 90% Drop

Rocapuldencel-T is the company’s most advanced product candidate, currently in Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.

“We appreciate Lummy’s continued commitment to Argos and the Rocapuldencel-T development program,” stated Jeff Abbey, CEO of Argos. “Given the complexity of the manufacturing process for Rocapuldencel-T, we were pleased to complete this important milestone in our alliance.

Argos Therapeutics Inc. (NASDAQ:ARGS) remains subdued after feeling the full effect of selling pressure since the start of the year. The stock has shed more than 90% of its total market value this year, as it continues to trade in a strong downtrend. It faces immediate support at $0.14, below which it could drop to its 52-week low of $0.14.

Argos Therapeutics Inc. (NASDAQ:ARGS) will announce its third quarter financial results for the three months ended September 30, 2017, on November 9, 2017. The financial results could have an impact on the direction of trade of the stock, depending on its outcome.

Argos Pipeline

The immuno-oncology company is to provide an update on ongoing Phase 3 ADAPT clinical trial evaluating the use of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma. Argos Therapeutics enrolled a total of 462 patients into the trial.

In addition to Rocapuldencel-T, Argos Therapeutics Inc. (NASDAQ:ARGS) is also developing a separate Arcelis-based product candidate AGS-004 for the treatment of human immunodeficiency virus. The candidate drug is currently being evaluated in combination with vorinostat, a latency reversing drug. The Nation Institute of Health has provided a portion of the funding for the candidate drug’s development.

Separately, Argos Therapeutics Inc. (NASDAQ:ARGS) has appointed Richard Morrison to its board of directors. He will serve as a Class III director and in the audit committee. Morrison joins the company with vast experience in the pharmaceutical and finance industry.

“Dick has considerable pharmaceutical industry and financial expertise, and we look forward to the benefit of his experience as we seek to advance our novel pipeline of individualized immunotherapies directed at important diseases, including metastatic renal cell carcinoma and HIV,” said Chairman, Hubert Birner.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Argos Therapeutics Inc (NASDAQ:ARGS)

Argos Therapeutics Inc (NASDAQ:ARGS) Stock Rises on Announcement

Argos Therapeutics Inc (NASDAQ:ARGS)

Shares of Argos Therapeutics Inc (NASDAQ:ARGS) rallied 12.65% after the company confirmed the dosing of the first HIV patient with AGS-004 dendritic cell therapy. The Phase 2 HIV eradication trial is being conducted in partnership with the University of North Carolina.

ARGS Stock Performance

The patient dosing marks the first time that an HIV patient has received a therapy utilizing RNA antigens from his latent lateral reservoir. The news did little to reverse the direction of ARGS stock as it continues to languish around all-time lows.

The stock is currently trading in a tight $0.21 – $0.25 per share range. Argos Therapeutics Inc (NASDAQ:ARGS) has underperformed the overall industry having shed more than 80% in market value since the start of the year. It awaits to be seen if the HIV trial is the catalyst that will help push the stock up from the current trading levels.

Argos Therapeutics Inc (NASDAQ:ARGS)
One month ARGS stock price chart

HIV Trial

The use of the RNA antigens from the patient’s latent reservoir was prompted by the fact the latent reservoir is where the HIV virus is most dominant, hidden from attack by the immune system. Current treatments agents have struggled to target the HIV virus in the reservoir rendering them inefficient.

The ongoing trial seeks to test whether boosting antiviral immunity with AGS-004, known to stimulate T-cells that attack HIV infected cells, will help expose the virus to the immune system to facilitate their eradication. According to Argos Therapeutics Inc. (NASDAQ:ARGS), the isolation of specific viral antigens from patients own could enable more focused immune system attack on the HIV virus.

“We believe that the new manufacturing process may allow AGS-004 to generate immune responses that are much better matched to the viral variants that will emerge during latency reversal with vorinostat treatment and, therefore, maximize the opportunity for viral clearance,” said Charles Nicolette, Chief Scientific Officer of Argos.

Argos Therapeutics Inc (NASDAQ:ARGS) has already enrolled four patients who will receive the AGS-004 manufactured using RNA antigens derived from infectious plasma. Results from ongoing Phase 2 eradication trial continues to be well tolerated.

Argos Therapeutics Inc (NASDAQ:ARGS) is funding the AGS-004 trial with finances provided by the National Institute of Health and the National Institute of Allergy and Infectious Diseases as well as Collaboratory of Research for Aids Eradication.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Argos Therapeutics Inc (NASDAQ:ARGS) Shares Bottom Before Rising

Argos Therapeutics Inc (NASDAQ:ARGS)

Argos Therapeutics Inc (NASDAQ:ARGS) shares gained over 5% in spite of establishing a new 52-week low before the end of today’s trading. It was a stange trading day for Argos Therapeutics Inc (NASDAQ:ARGS). Shares closed on Tuesday at $0.30 then gapped up to open at $0.41 before hitting their interday high of $0.47 – then ARGS shares plummeted to a new 52-week low of $0.29 before closing at $0.31.

ARGS shares spiked early on news of immunogenicity data from a study of AGS-004 dendritic cell therapy in patients treated during acute HIV infection – published in the Journal of AIDS Research and Human Retroviruses. The study achieved its primary endpoint, with all six patients demonstrating a positive immune response. The favorable results of this study provide support for Argos Therapeutics Inc (NASDAQ:ARGS) ongoing HIV eradication study in which AGS-004 is being administered in combination with vorinostat, a latency-reversing drug. This study is being conducted at the University of North Carolina, with planned enrollment of up to 12 patients and with initial data expected in early 2018.

Argos Therapeutics Inc (NASDAQ:ARGS) shares have been trading under $1 since March of this year. Shareholders have lost over 93% YTD, and over 95% for the year. At least two investment firms lowered the stock’s rating in 2017. Shareholders have never seen a profit. In 2012 the loss per share was (-$0.61) and that loss expanded annually until 2016 when the loss shrank to come in at (-$1.66). Sales have had a downward trajectory. In 2012 sales were posted at $7 million but by 2016 the sales figure was just $0.90 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARGS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

What Is In Store For Argos Therapeutics Inc (NASDAQ:ARGS)?

Argos Therapeutics Inc (NASDAQ:ARGS)

Earlier in February Argos Therapeutics Inc (NASDAQ:ARGS) reported that its Phase III clinical study of ADAPT was unsuccessful. The study looked at utilizing Rocapuldencel-T in combination with sunitinib malate against sunitinib/other SOC therapies alone for the improvement in OS in subjects with metastatic Renal Cell Carcinoma.

The Independent Data Monitoring Committee determined the lack of efficacy with Roca-T, and concluded that no considerable benefit in patient survival was shown in the trial arm of this study.

The current scenario

Prior to the Phase III ADAPT study, Roca-T faced a phase II study with 21 patients which demonstrated promising enough results in OS benefit together with a tolerable safety profile to assure a Phase III trial exploring the advantage bringing Roca-T to standard of care treatments in advanced metastatic kidney cancer.

Some concerns related to this trial were the small sample size of subjects, lack of a side-by-side control group, along with the dismal performance in the deprived risk group which did not demonstrate an improved OS advantage relative to historical control norm statistics.

Argos Therapeutics Inc (NASDAQ:ARGS) management resolved most of these concerns in the Phase III study by taking more intermediate risk subjects, along with fewer risk elements, and kept dosing of Roca-T across disease progression in the study arm when subjects were switched from one treatment alternative to another.

With the latest report of Roca-T’s absence of a survival benefit in the larger ADAPT study, share price has declined by more than 75%.

The IDMC suggested it be stopped as a statistically notable survival benefit was not being demonstrated in the study arm relative to control. In their suggestion, they did not note a chance where such an advantage could be met if the study was enabled to continue until 100% of patient deaths happened in both arms.

Overall survival advantage of almost 6 months per significant OS curve separation in the study arm was the primary objective in the Argos Therapeutics Inc (NASDAQ:ARGS) ADAPT study. If the IDMC suggested stopping the study depending on failure to fulfill these criteria, it can happen that survival benefit, if any, can be less than 6 months.

The stock price of Argos Therapeutics Inc (NASDAQ:ARGS) has a value of $0.383 while the 52 week low stands at $0.31. The 52 week high, made on April 18, 2016, stands at $13.97.

3/30/2017
Ticker Symbol ARGS
Last Price a/o 3:21 PM EST  $0.38
Average Volume 677.45K
Market Cap (mlns) $ 23.55M
Shares Outstanding (mlns) 61.43M
Share Float (mlns) 21.48M
Inside Ownership 1.00%
Short Float 13.65%
Short Interest Ratio 4.33
Quarterly Return -92.10%
YTD Return -92.18%
Year Return -94.01%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.